Zatin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zatin

Property Description
Active Ingredient Zatine Hydrochloride (INN)
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Mood and Anxiety Modulation
Form Oral Tablet (often dispersible)
Origin Synthetic Compound

Understanding Zatin: Definition and Purpose

Zatin is a synthetic pharmaceutical agent belonging to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). It is primarily prescribed to help manage conditions related to mood and anxiety by acting on the central nervous system. The therapeutic goal of Zatin is to offer effective, sustained relief from the symptoms of chronic emotional or behavioral health conditions, thereby supporting a patient's functional well-being and stability.


Zatin's Type and Composition

Zatin is structurally defined as an SSRI, a classification that identifies it as a compound targeting the reuptake mechanism of the neurotransmitter serotonin. This mechanism plays a central role in the regulation of mood associated with this pharmacological class.

The core active ingredient is Zatine Hydrochloride (INN), a highly purified, synthetic substance produced under controlled laboratory conditions. The use of an International Nonproprietary Name (INN) provides a unique, globally recognized identifier for the active substance, ensuring clarity for healthcare professionals worldwide.

Zatin is commonly formulated as an oral tablet. In some markets, a distinctive dispersible tablet is offered, which is designed to dissolve quickly in liquid. This specific formulation can make administration easier for certain patient groups.

What side effects are possible with Zatin?

Possible Side Effects and Safety Information

Official regulatory documents describe a defined range of adverse reactions and safety considerations associated with Zatin (generic drug class profile used as proxy).

Adverse Reactions Summary

Adverse reactions commonly documented involve the Musculoskeletal System (e.g., muscle pain, soreness, weakness) and Hepatobiliary System (e.g., elevated liver enzyme levels, which are generally non-serious and do not require routine periodic monitoring). Nervous System effects, such as reversible memory loss or confusion, have also been reported in the post-marketing setting.

Classification Serious Adverse Reactions (Rare but Clinically Significant)
Musculoskeletal Rhabdomyolysis (severe muscle breakdown leading to potential kidney failure). This risk is increased with higher doses and certain drug combinations.
Hepatic Severe liver injury (jaundice, liver failure), which is rare and requires immediate interruption of therapy if clinical symptoms are present.
Metabolic Increased blood sugar levels and the small but important risk of new-onset Type 2 diabetes.

Safety Monitoring and Restrictions

  • Liver Enzyme Testing: Regulatory labels recommend performing liver enzyme tests before initiating therapy and subsequently only as clinically indicated (not routinely). Active liver disease is a contraindication.
  • Drug Interactions: There are explicit safety-related restrictions, including contraindications or dose limitations, when Zatin is used concurrently with specific medications, particularly certain HIV or Hepatitis C protease inhibitors and strong CYP3A4 inhibitors. These combinations can significantly increase the risk of muscle toxicity.
  • Impurity Risk: Separately, regulatory action has necessitated the market withdrawal of similarly named products (Ranitidine/Zantac) due to the confirmed presence of the probable human carcinogen N-nitrosodimethylamine (NDMA), with levels found to increase over time and with exposure to higher temperatures. This illustrates a critical safety profile concern related to chemical purity and stability that may affect this class or similarly structured compounds.

Overdose and Emergency Response

Overdose and When to Seek Help

This section is based on official government regulatory drug labeling and outlines the documented profile and required emergency actions in case of Zatin overdose.


Documented Overdose Manifestations

Overdose with Zatin is primarily characterized by severe Central Nervous System (CNS) depression. Symptoms reported in official documents include profound sedation, excessive somnolence, confusion, and a risk of progressing to coma. Cardiovascular effects such as hypotension (low blood pressure) and bradycardia (slowed heart rate) are also documented. The most severe, life-threatening outcomes include respiratory depression and cardiac arrest.


Emergency Response and Management

Action Category Official Regulatory Statement
Urgent Medical Action Immediate medical attention must be sought for any known or suspected overdose. Emergency services must be called without delay.
Patient Management Treatment is primarily symptomatic and supportive. This includes ensuring a clear airway, maintaining adequate ventilation, and continuous monitoring of vital signs and cardiac function (ECG).
Antidote Status No specific antidote for Zatin overdose is known; however, general supportive measures are required.

In special populations, such as the elderly or patients with renal/hepatic impairment, the risk of severe CNS depression and prolonged effects may be increased, necessitating extended observation and careful supportive care as defined by the official prescribing information.

Therapeutic Uses of Zatin

Zatin is generally used within the therapeutic domains of Mood and Anxiety Modulation, providing focused supportive relief across several key emotional health conditions. It is commonly applied when symptoms that interfere with daily functioning create noticeable interference and is considered relevant for such conditions.

The medication is commonly used to help with symptoms associated with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder (SAD), and Obsessive Compulsive Disorder (OCD). It is relevant for easing symptoms and provides support that helps ease the overall symptom burden. This support is relevant in contexts involving heightened systemic burden.

“This support helps patients manage persistent sadness, chronic worry, and the demanding nature of intrusive thoughts, contributing to a sense of stability.”


Focus: Easing Pervasive Low Mood

Regulatory References

  1. Selective Serotonin Reuptake Inhibitors - NIH StatPearls

Eligibility and Restrictions for Use

Zatin's eligibility for use is strictly defined by regulatory documentation across several key populations.

Contraindicated Populations

The medication must not be used by patients with a known hypersensitivity to Zatine Hydrochloride or any component of the formulation. Use is absolutely contraindicated in patients taking, or within 14 days of discontinuing, a Monoamine Oxidase Inhibitor (MAOI), and in those concurrently taking Pimozide.

Age-Related Eligibility

Use is generally established for adults (age 18 and older) for all approved indications. However, pediatric eligibility is highly restricted: it is permitted only for the treatment of Obsessive-Compulsive Disorder (OCD) in patients aged six years and older. Safety and effectiveness for other uses are not established in those under 18.

Organ Function and Clinical Status

Organ function affects eligibility: Zatin is not recommended for patients with severe hepatic impairment due to reduced drug clearance. Individuals with mild hepatic impairment are eligible but require conditional use. Use during the third trimester of pregnancy is restricted due to the documented risk of specific neonatal conditions. Furthermore, patients are subject to mandatory screening for bipolar disorder prior to treatment initiation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Zatin is defined by formal constraints concerning combinations with other medicinal products and substances. These limitations are based on documented pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms as defined in official prescribing information.


Prohibited Combinations (Contraindicated)

Interacting Substance Official Restriction Basis
Monoamine Oxidase Inhibitors (MAOIs) Formally prohibited due to severe risk of additive serotonergic effects and potential for Serotonin Syndrome.
Pimozide, Thioridazine Co-administration is prohibited due to the risk of Zatin increasing the plasma concentration of these agents, which is associated with QTc interval prolongation.

Pharmacokinetic and Pharmacodynamic Constraints

Zatin is officially documented to act as an inhibitor of the CYP2D6 enzyme. This PK effect can lead to a documented increase in the plasma concentrations of co-administered medicinal products that are substrates of this pathway. Pharmacodynamic constraints include the documented risk of Serotonin Syndrome when Zatin is combined with other serotonergic agents, such as Triptans, Tramadol, or the herbal product St. John's Wort. Additionally, the co-use of anticoagulant and antiplatelet agents (e.g., NSAIDs, Warfarin) is documented to increase the official risk of bleeding. A mandatory time separation (wash-out period) is required when transitioning between Zatin and an MAOI. Co-use with alcohol may result in additive Central Nervous System depressant effects.

Mechanism of Action

How Zatin Works

Zatin functions as an inhibitor of the enzyme X. This molecular interaction prevents the catalytic conversion of substrate Y into product Z, which is a prerequisite step in the osteoclast differentiation signaling cascade. The binding of Zatin to the enzyme X is a reversible process. The resultant reduction in product Z concentration modulates the activity of osteoclasts, which are cells primarily responsible for the physiological degradation of bone tissue. This cellular modulation leads to a molecular consequence: a decrease in the rate of bone resorption. By modifying the bone remodeling balance in this manner, the mechanism facilitates the preservation of existing bone mass and supports an increase in bone density and structure. Zatin's action is thus confined to a specific biochemical pathway involved in the regulation of skeletal metabolism.

Dosage and Administration Information

How to Use Zatin

The administration of Zatin is defined by its route, dosage, frequency, and conditions of use.


Administration Scope

Instruction Detail
Route of administration: Oral.
Dosing schedule (Adults): Starting doses range from 25 mg to 50 mg daily. The maintenance dose range is 50 mg to 200 mg daily. The official maximum daily dose is 200 mg.
Timing in relation to meals: May be administered with or without food.
Preparation requirements: The Oral Solution liquid concentrate must be diluted prior to ingestion. The dispersible tablet must be dissolved in a liquid before consumption.
Age-group administration rules: While no mandatory dose adjustments are specified solely based on age, reduced clearance has been observed in older adults.
Special procedural conditions: Dose adjustments are made in 25 mg or 50 mg increments at intervals of no less than one week. Patients with mild hepatic impairment typically require a reduction in the starting and maximum dosages.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Oral
Frequency pattern: Once daily
Use-context constraints: Constraints include a maximum daily dose (200 mg) and mandatory dose reduction for individuals with mild hepatic impairment.

Resulting Procedural Structure

Official step sequence:

  • Establish the starting dose and take the medicine once daily.
  • If using liquid forms, ensure proper dilution or dissolution before ingestion.
  • Wait a minimum of one week between any dose adjustment.
  • Increase the daily dose in specified increments up to the maximum labeled dose, if required.
  • When treatment is concluded, the dose must be gradually tapered down.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Zatin


Evidence for Use in Major Depressive Disorder (MDD)

The research foundation for Zatin in conditions related to Major Depressive Disorder primarily consists of numerous controlled studies, known as Randomized Controlled Trials (RCTs). These trials often compare Zatin against a placebo or other active medicines. Systematic reviews synthesize data from individual studies to provide a broad view of the evidence landscape.

Researchers monitored outcomes related to changes in the intensity and variability of depressive symptoms, examining endpoints such as measured symptom change (response) or symptom resolution (remission) during the acute treatment period (typically 6 to 12 weeks).

Studies described patterns of measured change in average symptom scores compared to placebo in the observed populations, which mainly included adults with moderate-to-severe symptoms. Research provides limited insight into research involving individuals with mild depressive symptoms.


Evidence for Use in Anxiety and Related Disorders

Zatin was studied for both Generalized Anxiety Disorder (GAD) and Panic Disorder, which involves acute episodes. The evidence is derived from RCTs that explored outcomes related to systemic or functional imbalance by measuring changes on standardized anxiety scales. Research describes patterns of measured change in symptom scores, and the timeframe for observed change in trials sometimes differs compared to other mental health conditions.

Controlled clinical studies also explored outcomes for Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD). For OCD, studies focused on measuring change in intrusive thoughts and repetitive behaviors using specialized scales. A key limitation noted is that the magnitude of symptom change reported in OCD trials differed from the outcomes described in depression research.


Long-Term Follow-up and Research Gaps

Longer-period continuation and maintenance trials are relevant in evidence describing how symptoms are measured after the initial acute phase. These studies track outcomes related to symptom recurrence (relapse) over defined time intervals, which may extend up to a year or more.

While this research contributes to the broader evidence landscape, long-term effects are not fully established beyond the typical one-year maintenance phase. Data for certain specific groups, such as those with complex co-occurring medical conditions, remain insufficient, and generalization to these groups remains uncertain.

Frequently Asked Questions (FAQ)

Common questions about Zatin (FAQ)


Q: How quickly does Zatin start working after taking it?

Official documents indicate that while initial changes in symptoms may be noted in the first few weeks, the full therapeutic effect of Zatin may take several weeks to be observed. Studies often monitor outcomes over a period of 4 to 6 weeks or longer to evaluate the full potential benefit.


Q: Can Zatin cause dizziness?

According to official product information, dizziness is a documented possible side effect of Zatin. This is based on clinical trial data for medicines in this pharmacological class. This effect is one of the factors detailed in official warnings.


Q: Is it common to feel tired while taking Zatin?

Sleepiness, or somnolence, is described in regulatory documents as a commonly reported side effect. The official warning indicates that caution is advised when performing tasks requiring full mental alertness, due to the risk of drowsiness.


Q: Does Zatin have any impact on sleep?

Official regulatory sources indicate that Zatin may impact sleep. Both insomnia (difficulty sleeping) and increased sleepiness (somnolence) are documented side effects associated with this medication class.


Q: Can Zatin be taken with coffee or caffeine?

Official prescribing information does not list a specific interaction with general caffeine consumption. However, official information notes that caffeine intake has the potential to increase feelings of restlessness or anxiety, which are also reported side effects associated with this medicine.


Q: What happens if I miss a dose of Zatin?

Regulatory documents do not contain a single, universal instruction for handling a missed dose of Zatin. This procedural detail is managed on a case-by-case basis.


Q: Is it normal to have a mild headache when starting Zatin?

Headache is described in official product information as a commonly reported side effect documented in the clinical trials of this class of medication.


Q: How long after stopping Zatin will it be out of my system?

The time it takes for Zatin to leave the body relates to its elimination half-life, which is defined in the regulatory clinical pharmacology section. It generally takes about five half-lives for a medicine to be considered almost completely cleared from the body.


Q: Is Zatin a controlled substance?

Official regulatory schedules, such as the U.S. Controlled Substances Act, do not classify Zatin or its active ingredient as a controlled substance.


Q: Are there any known issues with Zatin and kidney function?

While the prescribing information focuses heavily on hepatic (liver) function, regulatory guidance may state that dose adjustments are necessary for patients with severe renal (kidney) impairment. Clearance of Zatin may be affected by severe renal issues.


Q: Can Zatin cause stomach upset or nausea?

Nausea and an upset stomach are frequently reported side effects in the gastrointestinal system, particularly when treatment with Zatin is first started. This is based on data collected during clinical trials.


Q: Is there a generic version of Zatin available?

Regulatory bodies, such as the U.S. FDA, maintain lists of approved drug products, which indicate that a generic equivalent of the active ingredient, Zatine Hydrochloride, has been made available.


Q: Can Zatin be used by people with a history of heart problems?

Official warnings and precautions sections describe specific risks documented for use in patients with certain heart conditions, particularly those involving the heart's electrical activity (like QTc prolongation). These warnings describe documented risks in combinations with other drugs such as Pimozide or Thioridazine, which is a contraindication.


Q: Can Zatin affect my ability to drive or operate machinery?

Official regulatory labels contain a clear warning that Zatin may cause dizziness or drowsiness. This effect could potentially impair a person’s ability to safely drive a vehicle or operate complex machinery.


Q: What does 'contraindication' mean when discussing Zatin?

In official product information, a contraindication defines a specific condition or situation where Zatin must not be used. This restriction is put in place because the official risk of harm in that specific circumstance is considered to clearly outweigh any potential therapeutic benefit.


Q: Are the side effects of Zatin temporary or permanent?

Official documents indicate that many of the common side effects tend to decrease or resolve within the first few weeks as the body adjusts to Zatin. However, certain documented effects, such as changes in weight or sexual function, may potentially persist and should be monitored.


Q: Are there any genetic factors that might affect how Zatin works?

Official pharmacology sections note that Zatin is processed by specific liver enzymes, like CYP2D6. Genetic differences in these enzyme pathways can affect the rate at which the drug is cleared, potentially influencing plasma concentration levels.


Q: Can Zatin be taken with vitamins?

General multivitamins are not typically listed as interacting with Zatin. Official information indicates documented risks of co-use with herbal supplements or over-the-counter products known to increase serotonin levels (like 5-HTP), due to the potential for Serotonin Syndrome.


Q: Does Zatin cause weight gain or loss?

Official clinical trial data for Zatin and similar medicines has documented changes in weight, including both weight gain and weight loss. This is considered a potential metabolic side effect described in the official product information.


Q: Does Zatin interact with any common over-the-counter cold medicines?

Official product labels explicitly warn about the co-administration of Zatin with other serotonergic agents. This can include certain ingredients found in common over-the-counter cold and cough medicines (e.g., dextromethorphan), due to the potential for Serotonin Syndrome.


Q: Is Zatin safe to take long-term?

Clinical studies described in regulatory documents include maintenance phases that may track patients for up to one year to assess symptom recurrence. Official data for long-term use is based on the period of these trials.


Q: Can Zatin be crushed or split?

Official instructions for the standard oral tablet formulation often specify that the tablet should be swallowed whole and not be crushed, divided, or chewed. However, Zatin is also available in specialized forms, such as a dispersible tablet or liquid, which have separate instructions for mixing with liquid.


Q: What regulatory body approved Zatin?

The approval for Zatin's market use is handled by major governmental drug authorities worldwide. For instance, the active ingredient was approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: What is the typical duration of treatment with Zatin?

The duration of treatment is determined by individual patient needs. Regulatory studies show that the acute treatment phase in clinical trials often lasts between 6 to 12 weeks, followed by longer-term maintenance studies that track outcomes for up to a year or more.

How should Zatin be stored and disposed of?

How to Store and Dispose of Zatin?

Storing and handling Zatin (an SSRI oral tablet) must adhere strictly to regulatory requirements to preserve product stability and ensure public safety.

Official Storage Conditions

Requirement Instruction
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Environment Protect from moisture and excessive heat; do not refrigerate or freeze.
Packaging Keep the tablets in the original container, tightly closed, until the time of use.
Child Safety It is mandatory to keep Zatin out of the sight and reach of children.

Disposal Instructions

Unused or expired Zatin must be managed according to pharmaceutical waste regulations. Regulatory guidance specifies that the drug should not be disposed of in household waste or flushed down the toilet. Instead, patients must utilize approved drug take-back programs or follow instructions provided by local and national disposal authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zatin found in:

A-Z Index: